Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / November 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Neurogene Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Neurogene Inc. (NGNE)
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on November 11, 2024, reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Neurogene Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Neurogene Inc. (NGNE)
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on November 11, 2024, reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / November 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
NGNE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Neurogene Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on November 11, 2024, reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome.
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / November 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
